8 July 2025 in Pathology - Research and Practice
AFAndarz Fazlollahpour-Naghibi
Andarz Fazlollahpour-Naghibi
+3
14 May 2026 in Immunity, Inflammation and Disease
Cancer is a significant global health concern and ranks as the second most common cause of death on a worldwide scale. A combination of hereditary and lifestyle variables, such as diet, smoking, alcohol consumption, physical exercise, and the gut microbiota, impacts cancer development. Dysbiosis, an imbalance in gut microorganisms, can promote cancer. Conversely, probiotics have the potential to enhance gut health and restore immunological equilibrium. Prior research has demonstrated that probiotics exert a beneficial influence on gastrointestinal health and immunological function. Probiotics perform these beneficial actions by changing the kinds of bacteria that live in the gut, altering metabolic function, breaking down chemicals that cause cancer, enhancing the efficacy of immune checkpoint inhibitors, reducing inflammation, and stopping the production of compounds that cause cancer. This current comprehensive review underscores the need for innovative strategies to enhance cancer prevention and treatment, focusing on integrating probiotics into therapeutic approaches to mitigate the adverse effects of conventional cancer therapies, improve patient outcomes, and prevent cancer.
16 June 2026 in Infectious Agents and Cancer
Epidermodysplasia verruciformis (EV) is a rare genodermatosis resulting from mutations in the EVER1/EVER2 genes, that increase vulnerability to beta-human papillomavirus (β-HPV) infection. The acquired form (AEV) develops in immunocompromised individuals, particularly organ transplant recipients, and typically manifests as pityriasis versicolor-like macules on sun-exposed areas. However, lesions confined to non-sun-exposed regions, especially the genitalia, are exceedingly uncommon and may be misdiagnosed. We report the case of a 38-year-old woman, nine years post-renal transplantation and on long-term triple immunosuppressive therapy (cyclosporine, mycophenolate mofetil, and prednisolone), who presented with progressive, non-pruritic, well-demarcated hypopigmented macules localized exclusively to her labia majora and mons pubis. The lesions were initially misdiagnosed and unsuccessfully treated as tinea versicolor. A skin biopsy revealed histopathologic features characteristic of EV, including enlarged keratinocytes with blue-gray cytoplasm and perinuclear halos and koilocytotic changes. This case emphasizes that AEV should be considered in the differential diagnosis of genital hypopigmented lesions in immunosuppressed patients. Accurate histopathologic evaluation is crucial for timely recognition, appropriate management, and ongoing surveillance to prevent missed malignant transformation.